glp-1 agonist Classification of currently available glucagon-like peptide-1 receptor A Closer Look at the
Description
2023), NNC9204-1177 (Friedrichsen et al
For context on the broader legal status of peptides in sports and research contexts, that guide provides a useful framework
Strength training can help preserve muscle mass during treatment and prevent weight regain after stopping the medication
The FDA also recommends examining hard clinical endpoints such hepatic decompensations, transplant free survival, and all-cause mortality, although these results are not necessarily needed prior to drug approval given the long length of follow up potentially required
